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Brief Definit ive Report
Allogeneic hematopoietic cell transplantation 
(allo-HCT) is an established treatment option 
for a variety of hematological malignancies. 
Worldwide, allo-HCT is performed >25,000 
times annually (Pasquini and Wang, 2012). Donor 
T cells present in the allograft contribute to the 
efficacy of allo-HCT, and mediate the graft-
versus-leukemia (GvL) effect. Unfortunately, 
donor T cells can also target nonmalignant host 
tissues, leading to a severe complication known 
as graft-versus-host disease (GvHD; Ferrara et al., 
2009). Acute GvHD grade 2–4 occurs in 40–
50% of the allo-HCT patients and is responsi-
ble for considerable morbidity and mortality 
( Jacobsohn and Vogelsang, 2007). Although 
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The success of allogeneic hematopoietic cell transplantation is limited by acute graft-
versus-host disease (GvHD), a severe complication accompanied by high mortality rates. 
Yet, the molecular mechanisms initiating this disease remain poorly defined. In this study, 
we show that, after conditioning therapy, intestinal commensal bacteria and the damage-
associated molecular pattern uric acid contribute to Nlrp3 inflammasome–mediated IL-1 
production and that gastrointestinal decontamination and uric acid depletion reduced GvHD 
severity. Early blockade of IL-1 or genetic deficiency of the IL-1 receptor in dendritic cells 
(DCs) and T cells improved survival. The Nlrp3 inflammasome components Nlrp3 and Asc, 
which are required for pro–IL-1 cleavage, were critical for the full manifestation of GvHD. 
In transplanted mice, IL-1 originated from multiple intestinal cell compartments and exerted 
its effects on DCs and T cells, the latter being preferentially skewed toward Th17. Compat-
ible with these mouse data, increased levels of active caspase-1 and IL-1 were found in 
circulating leukocytes and intestinal GvHD lesions of patients. Thus, the identification of a 
crucial role for the Nlrp3 inflammasome sheds new light on the pathogenesis of GvHD and 
opens a potential new avenue for the targeted therapy of this severe complication.
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IL-1 receptor antagonist (IL-1RA) Anakinra starting 24 h be-
fore conditioning (day 1) significantly improved survival of 
mice in comparison to littermates treated with placebo, whereas 
there was no protection when treatment was initiated on day 5 
(Fig. 1 A). Likewise, mice treated with a selective neutralizing 
anti–IL-1 antibody 24 h before conditioning experienced 
improved body weight (not depicted) and prolonged survi-
val whereas later treatment (day 5) was not effective (Fig. 1 B). 
Notably, treatment with the neutralizing anti–IL-1 antibody 
did not affect GvL-effects or immune reconstitution (unpub-
lished data). To assess which target cell populations are impacted 
by IL-1, we quantified the expression of IL-1R in different 
cell populations known to have a role in GvHD development 
(Bryson et al., 2004; Shlomchik 2007). We observed a signifi-
cant increase of IL-1R expression on CD11c+ DCs, CD4+  
T cells, and CD8+ T cells peaking on day 3 after allo-HCT 
(Fig. 1 C). Consequently, transplantation of allogeneic IL-1R–
deficient T cells resulted in delayed GvHD-induced mortal-
ity compared with the transfer of IL-1R–competent T cells 
(Fig. 1 D). Furthermore, transplantation of IL-1R/ DCs led 
to reduced GvHD mortality when compared with the transfer 
of IL-1R+/+ cells (Fig. 1 E). These data support the critical role of 
IL-1 in the early phase of GvHD and demonstrate that IL-1  
exerts its proinflammatory effects on both T cells and DCs.
The Nlrp3–inflammasome regulates acute GvHD
Asc constitutes an essential adaptor protein for caspase-1–
mediated pro–IL-1 processing by distinct inflammasomes 
(Martinon et al., 2009). To delineate the potential involvement 
of Asc-containing inflammasomes in the pathogenesis of acute 
GvHD, we used Asc/ mice as donors or recipients. In Asc/ 
recipient mice, we observed delayed GvHD-induced mortal-
ity and a lower cumulative GvHD score compared with 
Asc+/+ or Asc+/ littermates (Fig. 2, A and B). Conversely, Asc 
deficiency of the donor did not influence GvHD severity 
(unpublished data). Next, we used Nlrp3/ mice as donors 
or recipients for allo-HCT to assess the involvement of the 
Nlrp3 inflammasome in acute GvHD. When Nlrp3/ mice 
were used as recipients, GvHD was significantly delayed com-
pared with WT controls at different T cell dosages, with long-
term survivors in the Nlrp3-deficient group (Fig. 2, C and D). 
This finding correlated with decreased weight loss in Nlrp3/ 
recipients (not depicted), a significant reduction in the histo-
logical GvHD score in the intestines of Nlrp3/ allo-HCT 
recipients (Fig. 2 E) and was reproducible in two different 
GvHD models (not depicted). In contrast, Nlrp3 deficiency 
of the donor did not result in survival differences (unpub-
lished data). Moreover, treatment with glibenclamide, known 
to inhibit the Nlrp3 inflammasome, resulted in delayed and 
reduced mortality of allo-HCT WT recipients comparable to 
IL-1RA blockade with Anakinra. These effects were seen after 
conditioning with total body irradiation (TBI) or fludarabine/
CY (FLU/CY), demonstrating the relevance of the afore-
mentioned results for different conditioning regimes used for 
human allo-HCT (Fig. 2, F and G). However, protection from 
GvHD-mediated mortality through blockade of the Nlrp3 
different prophylactic regimens are currently used to reduce 
GvHD (Ram et al., 2009), the disease remains a significant un-
solved medical problem. Before allo-HCT, recipients undergo 
a conditioning regimen, consisting of cytotoxic drugs and 
-irradiation. Such a regimen induces tissue damage, allowing 
bacterial products to translocate from the skin and mucosa into 
the internal milieu, where they provoke a “cytokine storm” which 
results in inflammation in the host, activation of the recipient’s 
antigen-presenting cells, and a subsequent donor T cell–mediated 
allogeneic reaction, with further amplification of the cytokine 
response (Shlomchik 2007). However, the molecular events 
governing proinflammatory cytokine production upon condi-
tioning remain poorly understood. We have previously shown 
that activation of the P2X7 receptor is a critical step in the patho-
genesis of GvHD (Wilhelm et al., 2010). The main endogenous 
ligand for P2X7 is the damage-associated molecular pattern 
(DAMP) adenosine-5-triphosphate (ATP; Ferrari et al., 2006) 
which is released by damaged tissues upon conditioning, 
thereby contributing to systemic immune activation. In this re-
gard, binding of ATP to P2X7 can cause assembly and activa-
tion of the protein 3 (Nlrp3)-inflammasome, which contains 
NACHT, LRR and PYD domains. The term inflammasome 
refers to intracellular multiprotein complexes that control acti-
vation of inflammatory caspases such as caspase-1 and -11. In 
recent years, several studies have reported that the Nlrp3 inflam-
masome is the essential platform for caspase-1 activation in 
response to multiple distinct exogenous and endogenous stress 
or danger signals (Franchi and Núñez, 2012). For caspase-1 acti-
vation, Nlrp3 utilizes the adapter protein apoptosis–associated 
speck-like protein containing a CARD (Asc; Davis et al., 2011; 
Franchi and Núñez, 2012). Full activation of the Nlrp3 inflam-
masome leads to cleavage of the precursor protein pro–IL-1 
into its active form. As bioactive IL-1 fulfills many biological 
functions, including the induction of adaptive immune responses, 
its production by the Nlrp3 inflammasome is tightly controlled 
by transcriptional and post-transcriptional signals. Signal 1 can 
be provided by Toll-like receptors (TLRs) leading to NF-B–
mediated gene transcription, and is essential for the synthesis of 
the IL-1 precursor pro–IL-1 and Nlrp3. In addition, detec-
tion of the second stimulus (signal 2) triggers proteolytic pro-
cessing of pro–IL-1 into mature bioactive IL-1 by the Nlrp3 
inflammasome. Recently, it has been shown that microbiota 
induce IL-1 release via an Nlrc4-inflammasome and are essen-
tial for the development of Th17 responses in the intestine 
(Franchi and Núñez, 2012). Intriguingly, Th17 cells have been 
causally linked to instances of aggravated GvHD after allo-HCT 
(Fulton et al., 2012). Here, we demonstrate that the Nlrp3 
inflammasome regulates GvHD by detection of DAMPs in the 
conditioning phase and subsequent shaping of Th17 responses 
in the intestines of the recipient.
RESULTS AND DISCUSSION
IL-1 affects GvHD in the early phase after allo-HCT
To study the involvement of IL-1 in GvHD development we 
treated mice receiving allogeneic BM and T cells (allo-HCT) 
with different IL-1 inhibitors. Treatment with the recombinant 
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data). Furthermore, additional anti-TNF treatment starting at 
day 5 improved protection by the Nlrp3 inhibitor (Fig. 2 F), 
demonstrating an inflammasome-independent role for TNF 
in the pathogeneses of GvHD.
inflammasome was incomplete. This can be explained by the 
fact that Nlrp3 inflammasome inhibition by glibenclamide 
was only partial, as residual amounts of IL-1 and cleaved 
caspase-1 were still detectable in myeloid cells (unpublished 
Figure 1. Proinflammatory IL-1 has effects on both T cells and DCs while receptor antagonism or depletion reduces acute GvHD related 
mortality. (A) BALB/c mice underwent TBI followed by transplantation with C57/BL6 BM alone (n = 10) or C57/BL6 BM plus T cells, and were monitored 
for survival. Where indicated, mice received either vehicle (PBS; n = 16) or Anakinra (n = 10 per group). Treatment was started on day 1 or +5, as indi-
cated. The experiment was performed twice and the resulting survival data were pooled. (B) C57BL/6 mice underwent TBI followed by i.v. injection of C3H 
BM alone or C3H BM plus T cells and were monitored for survival. Where indicated, mice received either no treatment or an antagonistic anti–IL-1 anti-
body on day 1 or +5. The experiment was performed twice, and the resulting survival data were pooled. Survival of mice receiving anti–IL-1 antibody 
on day 1 versus day +5: P < 0.0001; n = 10 per group. (C) BALB/c mice underwent TBI followed by allo-HCT with C57/BL6 BM plus T cells. Expression of 
IL-1R on splenic donor type (H-2Kb+) CD4+, CD8+, and CD11c+ cells was analyzed by flow cytometry at the indicated time points after allo-HCT. Mean 
fluorescence intensity (MFI) is displayed for day 3 (filled square) and for day 10 (filled triangle) compared with the untreated group (open circle). Each 
data point represents an individual animal (n = 6 per group). The experiment was repeated twice and the resulting data were pooled. (D) BALB/c mice 
received TBI + C57/BL6 BM alone or with T cells from IL-1R+/+ (open circle) or IL-1R/ (filled square) donors and were monitored for survival. The experi-
ment was performed twice and the resulting survival data were pooled. IL-1R+/+ T cells versus IL-1R/ T cells: P = 0.0102; n = 10 per group. (E) C57BL/6 
mice underwent TBI followed by transplantation with BALB/c BM alone (n = 3) or BALB/c BM plus T cells (n = 10 per group). Mice that received T cells 
were additionally injected i.v. with DCs from IL-1R+/+ C57BL/6 mice (open circle) or DCs from IL-1R/ C57BL/6 mice (filled square) on day 0. The experi-
ment was performed twice, and the resulting survival data were pooled. DC IL-1R+/+ versus DC IL-1R/: P = 0.0002. ***, P < 0.0001; **, P < 0.001; *, P < 0.05.
 o
n






Published August 26, 2013
1902 The Nlrp3 inflammasome regulates GvHD | Jankovic et al.
mRNA after TBI in target tissues of GvHD. In addition to 
elevated pro–IL-1 levels in the intestines of irradiated mice 
(unpublished data), high levels of IL-1 mRNA were found 
in the intestinal tract and skin after TBI or BU/CY (BU/CY) 
conditioning (Fig. 3, A and B). Depletion of the microbial 
flora by antibiotic treatment diminished IL-1 mRNA lev-
els (Fig. 3 A). The observation that neomycin, which is not 
absorbed in the intestines, reduced IL-1 mRNA levels in 
the skin supports the concept that the initiating signal for 
acute GvHD arises in the intestine and that influencing the 
bacterial microflora can prevent systemic GvHD. Moreover 
Bacterial flora and uric acid induce IL-1
According to our data, which was obtained by neutralizing 
IL-1 in TBI-treated mice, we hypothesized that Nlrp3 inflam-
masome activation primarily occurs during the early condition-
ing phase before allo-HCT. However, the factors contributing 
to IL-1 production after conditioning are largely unknown. 
Yet, it is believed that translocation of bacterial products, 
defined as pathogen-associated molecular pattern (PAMPs), 
from the gastrointestinal tract through the mucosal barrier 
promotes the initiation of proinflammatory responses in acute 
GvHD (Holler et al., 2010). Therefore, we first quantified IL-1 
Figure 2. GvHD severity is reduced when recipients lack Asc or Nlrp3. (A and B) Asc/ or Asc+/ C57BL/6 mice (n = 6 per group) underwent TBI 
followed by allo-HCT with C3H BM plus T cells. As control groups, WT C57BL/6 mice that received TBI alone (n = 6) or TBI plus C3H BM (n = 6) were used. 
Graphs show survival curves after transplantation (A) and histopathological scoring (apoptosis, inflammation) of the GvHD target organs (small intestine, 
large intestine and liver) on d10 after transplantation (B). The experiment was performed three times with similar results. One representative experiment 
is shown. (C–E) Nlrp3/ or Nlrp3+/+ C57BL/6 mice (n = 10–12 per group) underwent TBI followed by allo-HCT with BALB/c BM alone or BALB/c BM plus  
T cells. T cell doses were 105 (C), 106 (D), or 3 3 105 (E) as indicated. Graphs show survival curves after transplantation (C and D) and histopathological 
scoring (apoptosis, inflammation) of the GvHD target organs (small intestine, large intestine, and liver) on day 10 after transplantation (E). The experiment 
was performed twice, and the resulting survival data were pooled. (F) C57BL/6 mice underwent TBI, followed by transplantation with BALB/c BM alone  
(n = 10) or BALB/c BM plus T cells and were monitored for survival. Treatment was performed with PBS (n = 10), the Nlrp3 inhibitor glibenclamide (n = 16), or 
glibenclamide plus the TNF inhibitor Etanercept (n = 10) as indicated. Treatment with glibenclamide was started on day 0, and treatment with Etanercept 
was started on day 5. The experiment was performed twice, and the resulting data were pooled. (G) BALB/c mice were conditioned with FLU/CY based 
chemotherapy, followed by transplantation with C57/BL6 BM plus T cells, and then monitored for survival. Treatment was performed with vehicle (DMSO, 
n = 10), glibenclamide (n = 10), or Anakinra (n = 10). ***, P < 0.0001; **, P < 0.005; *, P < 0.05.
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Figure 3. Effects of TBI, chemotherapy, commensal bacteria, and uric acid on IL-1/TNF production. (A and B) RNA from the intestines and 
skin of mice receiving TBI (9 Gy) or chemotherapy (BU/Cyclophosphamide) was isolated 24 h after conditioning, and the expression of IL-1 and TNF 
was determined by quantitative PCR (qPCR). Neomycin (neo) or Ciprofloxacin (CPFL) were given starting 7 d before TBI, as indicated. Each data point 
represents an individual animal (n = 3) and the experiment was repeated 3 times. (C, left) Intestinal tract cells were isolated on d7 after allo-HCT, and 
the amount of intracellular IL-1 production was determined in the indicated cell populations after stimulation with PMA/ionomycin for 3 h. Shown 
are pooled results of six mice per group. (C, right) C57BL/6 hosts were transplanted (TBI, BALB/c BM+ T cells) and sacrificed 3 or 7 d after transplanta-
tion or left untreated (steady state). LPLs were isolated and directly analyzed for expression of CD11b, CD11c, donor/recipient markers, and intracel-
lular expression of pro–IL-1 by flow cytometry. Top graphs show myeloid subgating of live LPLs, bottom graphs show donor H2k expression versus 
pro–IL-1 of myeloid subpopulations from top row. Data from one of two independent experiments with similar results and multiple time point analy-
ses are shown. (D) RNA from the intestines of mice receiving TBI was isolated after 24 h and the expression of IL-1 was determined by quantitative 
PCR (qPCR). Each data point represents an individual animal (n = 4). The experiment was performed 3 times with similar results. (E) C57BL/6 mice 
received anti–IL-1 antibody or vehicle 24h before TBI or control treatment. RNA from the small intestine was isolated 40 h after TBI, and the expres-
sion of IL-1 was determined by quantitative PCR (qPCR). Each data point represents an individual animal (n = 4). The experiment was performed 
three times, with similar results. (F) BALB/c mice underwent different conditioning regimes: TBI alone (day 0; n = 3) or followed by allo-HCT with C57/
BL6 BM plus T cells (day 10; n = 4); BU/CY chemotherapy or FLU/CY chemotherapy alone (day 0, n = 5) or followed by allo-HCT with C57/BL6 BM plus 
T cells (day 3, n = 6) as indicated. Untreated mice (n = 9) served as control. At the indicated time points, peritoneal fluid was isolated and UA levels 
were determined. Each data point represents an individual animal, and the experiment was performed twice with similar results. (G) BALB/c mice  
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observed significantly increased UA levels in the peritoneal 
cavity after TBI-, BU/CY-, or FLU/CY-based conditioning 
and during GvHD compared with untreated mice (Fig. 3 F). 
Moreover, UA had a functional role in the pathogenesis of 
GvHD, as uricase given early (1 d before allo-HCT) resulted 
in improved survival (Fig. 3 G) and lower IL-1 serum levels 
(Fig. 3 H) compared with mice receiving placebo. However, 
later uricase treatment (day 5) was not protective (Fig. 3 G). 
Notably, uricase is used to reduce UA levels in patients with 
tumor lysis syndrome (Rampello et al., 2006). To assess the 
redundancy of multiple DAMP signaling, we adoptively trans-
ferred P2X7/ or P2X7+/+ DCs during BMT, either with or 
without priming with alum, an agent known to induce UA 
release (Kool et al., 2008). UA and ATP are both known 
activators of the Nlrp3 inflammasome, but with P2X7 relay-
ing signaling only after ATP and not alum sensing. Accord-
ingly, GvHD severity was increased when ATP-unresponsive 
P2X7/ DCs were primed with alum, pointing to non-
redundant roles of UA and ATP as GvHD-initiating DAMPs 
(unpublished data). Early intervention (day 1 prior TBI) 
with Anakinra or uricase was more effective than later treat-
ment (day 5; Figs. 1 A and 3 G), indicating that inflamma-
some-mediated activation of IL-1 occurs very early in GvHD 
pathogenesis. Together, our data show that conditioning before 
allo-HCT induces the release of PAMPs and DAMPs, trigger-
ing pro–IL-1 synthesis and Nlrp3 inflammasome activation, 
respectively, in the recipients and promoting an inflammatory 
response that ultimately impacts the development and sever-
ity of acute GvHD.
The Nlrp3 inflammasome regulates Th17 responses
The effector phase of acute GvHD involves alloreactive donor 
T cells. Recently, IL-17A–producing CD4+ T cells (Th17) cells 
have been shown to accumulate in the intestine in a colon 
inflammation model via an IL-1–dependent mechanism 
(Coccia, Harrison et al., 2012). To assess whether inflamma-
some activation and subsequent IL-1 production in the course 
of GvHD had an impact on Th17 responses, we first analyzed 
donor T cell compartments in Nlrp3/ allo-HCT recipients. 
We found reduced relative numbers of CD4+IL-17A+ T cells 
in the spleens of Nlrp3/ compared with Nlrp3+/+ recipients, 
whereas CD4+IFN-+ or CD4+IL-4+ cells (Fig. 4 A), naive 
T cells, effector memory T cells, or central memory T cells 
were unchanged (not depicted). The Nlrp3 inflammasome 
may also influence the differentiation of donor derived 
CD4+IL-17A+ T cells. To test this hypothesis in vitro, we per-
formed an allogeneic mixed lymphocyte reaction and co- 
incubated allogeneic splenic T cells with LPS-stimulated 
DCs sorted from the LP of intestines. IL-17 secretion by allo-
geneic T cells was significantly enhanced in the presence of 
chemotherapy-based conditioning caused increased active 
caspase-1 levels after allo-HCT (unpublished data). Thus, our 
data indicate that after irradiation the bacterial microflora in 
the gut provides the first signal leading to pro–IL-1 tran-
scription. This is consistent with the known role of microbial 
TLR activation causing NF-B–driven IL-1 gene transcrip-
tion (Akira and Takeda, 2004). Compatible with these results, 
gastrointestinal decontamination protocols are applied in sev-
eral transplantation centers to reduce the severity of acute 
GvHD (Beelen et al., 1999). Additionally, the levels of TNF, 
a proinflammatory cytokine known to contribute to acute 
GvHD pathogenesis, were significantly increased after TBI in 
the absence of antibiotics (Fig. 3 B). To determine the origin 
of IL-1, we analyzed different hematopoietic and nonhema-
topoietic cell types in allo-HCT–transplanted mice and found 
IL-1 production in DCs, myeloid cells, myofibroblasts, endo-
thelial cells, and fibroblasts isolated from the intestines (Fig. 3 C). 
Our observation suggests that multiple recipient cell subsets 
respond to conditioning by producing IL-1, which targets 
donor DCs and T cells. Indeed, a targeted deletion of Asc in a 
single compartment including donor keratinocytes, DCs, or 
myeloid cells was not sufficient alone to influence GvHD 
severity (unpublished data).
To delineate which cell populations contribute to IL-1 
production at early versus late time points, small intestinal 
lamina propria (LP) subsets were analyzed on days 0, 3, 
and 7 after allo-HCT. We observed that early after allo-HCT, 
host derived CD11b+ myeloid cells were the dominant pro– 
IL-1–expressing subset, whereas donor-derived DC subsets 
were only starting to infiltrate the LP (Fig. 3 C). At later time 
points (7 d after allo-HCT), however, donor-derived DC 
numbers increased significantly and became the main IL-1–
producing myeloid subset. T cells did not significantly con-
tribute to IL-1 production (unpublished data). These findings 
might also explain why Nlrp3-deficient recipients display an 
early but only partial protection from GvHD.
IL-1 mRNA levels were significantly reduced in the 
intestines of irradiated Nlrp3-deficient mice (Fig. 3 D). This 
observation suggested a rapid positive feedback from mature 
IL-1 on its own pro-form synthesis. This hypothesis was 
confirmed with the use of an anti–IL-1–neutralizing anti-
body, which also led to diminished IL-1 mRNA levels in 
irradiated Nlrp3-competent mice (Fig. 3 E).
In light of our data suggesting Nlrp3 inflammasome acti-
vation, we sought to identify DAMPs that could lead to this 
activation after conditioning and allo-HCT. Uric acid (UA) 
belongs to the class of DAMPs that potently trigger Nlrp3 
inflammasome activation (Martinon et al., 2006; Gasse et al., 
2009) and is known to be released from damaged cells. Hence, 
we assessed the role of UA in IL-1 release after TBI. We 
underwent TBI followed by allo-HCT with C57/BL6 BM alone (n = 10) or C57/BL6 BM plus T cells. Mice were treated with PBS (n = 16) or uricase start-
ing from day 1 forward or from day +5 forward (n = 10 per group), as indicated. The experiment was performed twice and the resulting survival data 
were pooled. (H) On day 3 after allo-HCT, serum was isolated from BALB/c mice that received treatment with PBS or uricase from day 0 forward. 
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indicative of an IL-1–dependent mechanism. A comparable 
reduction of Th17 commitment was observed when Anakinra 
was added to the same co-cultures between GMCSF-DCs 
and allogeneic splenic CD4 T cells (Fig. 4 C). Importantly, 
LPS-stimulated CD11c+CD11b+ DCs (Fig. 4 B), but not 
with LPS-stimulated CD11cCD11b+ DCs. Yet, IL-17 pro-
duction was completely abolished if Anakinra was added to 
the co-cultures containing CD11c+CD11b+ DCs, which is 
Figure 4. Nlrp3/Asc deficiency or IL-1 antagonism causes lower IL-17A production and alloreactive T cell expansion. (A) Splenocytes were 
isolated from untreated mice (n = 4) or Nlrp3+/+ or Nlrp3/ mice (n = 6 per group) receiving TBI+BM and T cells (BALB/c → C57BL/6 model) and analyzed 
for CD4+ T cell cytokine production by intracellular FACS staining after PMA/Ionomycin/Brefeldin A restimulation (left). A representative histogram of  
IL-17A–stained cells is shown (right). The experiment was performed two times with similar results. (B) Intestinal LPL from C57BL/6 mice were sorted into 
CD11b+CD11c and CD11b+CD11cmid populations. Sorting strategy and overlaid post-sorting FACS analysis of resulting CD11b+CD11c (green) or 
CD11b+CD11cmid (orange) populations are shown on the left. Cells were stimulated with or without LPS (20 ng/ml) and Anakinra (10 µg/ml) and co-incubated 
with BALB/c splenic CD4+ T cells. After 120 h, supernatants were analyzed for IL-17A. One representative of two independent experiments is shown.  
(C) BALB/c splenic CD4+ T cells were co-incubated with C57/BL6 GMCSF-DCs that were preexposed to increasing LPS concentrations with or without 
Anakinra (10 µg/ml). After 120 h of co-culture, the supernatant was analyzed for IL-17A by ELISA. One representative of four independent experiments is 
shown. (D) BALB/c naive splenic CD4+ T cells were incubated for 120 h with Nlrp3+/+ or Nlrp3/ GMCSF-DC that were preexposed to LPS at different 
concentrations and the supernatant was analyzed for IL-17A by ELISA. One representative of four independent experiments is shown. (E) CFSE-labeled 
BALB/c CD4+ T cells were co-cultured with LPS preexposed DC from Nlrp3+/+ or Nlrp3/ mice at different ratios for 96 h. One representative of four inde-
pendent experiments is shown. (F) BALB/c splenic CD4+ T cells were incubated for 120 h with Asc+/+ or Asc/ GMCSF-DC that were preexposed to LPS at 
different concentrations and the supernatant was analyzed for IL-17A by ELISA. One representative of four independent experiments is shown. (G) T cells, 
as in D, were restimulated with PMA (1 µM), ionomycin (100 nM), and Brefeldin A after co-culture with unprimed or 20 ng/ml LPS-primed DCs (Nlrp3+/+, 
Nlrp3/, or Anakinra-treated Nlrp3+/+) and analyzed by FACS for intracellular IL-17A, IFN-, and FoxP3. One representative of three independent experi-
ments is shown. ***, P < 0.0001; **, P < 0.001; *, P < 0.05.
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with data showing that IL-1R signaling is crucial for Th17 
polarization of naive T cells in multiple diseases, including coli-
tis models resembling intestinal GvHD (Coccia et al., 2012). 
However, we found that in addition to its requirement for 
Th17 induction, Nlrp3 in the APCs was also required for ef-
fective alloantigen-driven T cell proliferation, a hallmark of 
acute GvHD.
Cleaved caspase-1/IL-1 increase in human GvHD
Next, we evaluated inflammasome activation in a group of 
seven transplanted patients with and without GvHD. Cleaved 
caspase-1 was found in the peripheral blood leukocytes of 
patients with acute GvHD when stimulated with LPS, but 
were being almost absent in leukocytes of allo-HCT recipi-
ents without GvHD, despite stimulation (Fig. 5 A). The lev-
els of cleaved caspase-1 were also higher in intestinal lesions 
IL-6 and IFN- production in the GMCSF-DC co-cultures 
was not affected by addition of Anakinra, excluding toxic effects 
by the inhibitor (unpublished data). Next, we co-incubated 
LPS-stimulated DCs from Nlrp3/ mice with allogeneic WT 
T cells. We found a significant reduction in IL-17 production 
and CD4+ T cell expansion in the presence of Nlrp3/ DCs 
(Fig. 4, D and E). Similarly, incubation of T cells with allogeneic 
Asc/ DCs exposed to LPS resulted in lower IL-17A protein 
levels compared with those induced by WT DCs (Fig. 4 F). In 
contrast to the reduced number of CD4+IL-17A+ T cells, the 
numbers of CD4+IFN-+ T and T reg cells were not affected 
by Nlrp3–or Asc–deficiency in DCs (Fig. 4 G and not de-
picted). TNF and other major GvHD-related cytokines were 
not affected in Nlrp3-deficient recipients (unpublished data). 
Together, our results indicate that the Nlrp3 inflammasome 
regulates Th17 differentiation. These findings are compatible 
Figure 5. IL-1 and cleaved caspase-1 
are found at high levels in human tissues 
of patients developing acute GvHD. (A) The 
presence of cleaved caspase-1 was deter-
mined in PBMCs from patients undergoing 
allo-HCT after stimulation with LPS (50 ng/ml) 
for 6 h. GvHD severity is indicated above the 
individual patient sample. (B) The amount of 
cleaved caspase-1 was determined by immuno-
histochemistry of intestinal biopsies de-
rived from patients with or without GvHD. 
The cleaved caspase-1–positive cells were 
quantified by counting positive cells per high 
power field (HPF). (C) The amount of IL-1 
was determined in freshly isolated PBMCs 
from healthy volunteers or patients undergo-
ing allo-HCT and correlated with the inci-
dence of acute GvHD. The left panel 
represents a representative flow cytometry 
plot; the diagram on the right shows the 
quantification for all individuals. Each data 
point represents an individual (n = 14–17 per 
group). (D) Immunohistochemical staining for 
IL-1 was performed on intestinal biopsies 
and correlated with the severity of acute 
GvHD. One representative sample is shown. 
(E) Immunohistochemical staining for IL-17A 
was performed on intestinal biopsies and 
correlated with the severity of acute GvHD. 
One representative sample is shown. **, P < 
0.005; *, P < 0.05.
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IL-1 of the human biopsies was performed according to standard protocols. 
Human PBMCs were isolated by Ficoll density gradient separation and used 
for intracellular IL-1 staining or protein isolation and Western blot for 
cleaved caspase-1.
Mice. C57BL/6 (H-2Kb, Thy-1.2), BALB/c (H-2Kd, Thy-1.2), and 
C3H/He mice were purchased from Charles River or Harlan and from the 
local stock of the animal facility at Freiburg University Medical Center. Mice 
were used between 6 and 12 wk of age. Only gender-matched combinations 
were used for transplant experiments. All animal protocols were approved 
by the Committee on the Use and Care of Laboratory Animals at Freiburg 
University at Munich University and by the veterinary authorities of Zürich. 
IL-1R/ mice were provided by M. Freudenberg (Max-Planck Institute 
for Immunobiology and Epigenetics, Freiburg, Germany). Nlrp3/ and 
Asc/ mice were provided by J. Tschopp (University of Lausanne, Lausanne, 
Switzerland). The floxed ASCf/f line was previously described (Drexler et al., 
2012) and carried ASC flanked by two loxP sites (C57BL/6J background). 
ASCf/f mice were crossed with mice transgenic for K14-Cre orLysM-Cre, 
or with CD11c-Cre mice (Jackson ImmunoResearch Laboratories) on a 
C57BL/6 background.
BM-derived DC (BMDC) isolation. Single-cell suspensions from the 
BM of C57BL/6J or BALB/c mice were isolated, and DC maturation was 
achieved by addition of GM-CSF (10 ng/ml; R&D Systems) to the cultures 
for 7 d, as previously described (Reichardt et al., 2008).
BM transplantation model and histopathology scoring. Allogeneic 
BM transplants were performed as previously described (Zeiser et al., 2008). 
Recipients were given 5 × 106 BM cells after TBI with 9 Gy (BALB/c) or 
10–11 Gy (C57BL/6). Where indicated, mice received BU (20 mg/kg/d from 
day 7 to 4; Busilvex; Pierre Fabre Pharma) and CY (100 mg/kg/d from day 3 
to 2; Endoxan; Baxter Healthcare) i.p. as previously reported (Sadeghi et al., 
2008). For reduced intensity conditioning, mice received fludarabine (200 
mg/kg/d from day 8 to 4; Genzyme) and CY (60 mg/kg/d from day 3 
to 2) i.p., as reported (Turner et al., 2008). Day of stem cell injection was as-
signed as day 0, days before stem cell injection are numbered backward. T cell 
doses (CD4/CD8 MACS enrichment; Miltenyi Biotech) varied depending 
on the transplant model C57BL/6 → BALB/c (3 × 105), BALB/c → C57BL/6 
(3 × 105 or 105 or 10 × 105 when indicated) or C3H → C57BL/6 (2 × 106). 
Sections of small and large bowel samples collected on day 10 were stained 
with hematoxylin/eosin and scored by an experienced pathologist blinded to 
the treatment groups. GvHD was scored on the basis of a previously published 
histopathology scoring system (Kaplan et al., 2004; Wilhelm et al., 2010).
Generation of chimeric recipients with P2X7R deficiency of hema-
topoietic or nonhematopoietic tissues. WT/C57BL/6 recipients were 
given 5 × 106 WT or P2X7R/ BM cells (C57BL/6) intravenously after TBI 
with 9Gy (2 × 4.5Gy). The following donor/recipient pair was combined: 
P2X7R/ → P2X7R+/+ (hematopoietic system: P2X7R/). The second 
HCT (allogeneic; BALB/c → C57BL/6; T cell dose, 3 × 105) was performed 
at day 40 after the first HCT (syngeneic). To reconstitute chimeras with recip-
ient type DCs, we infused 3 × 106 DCs intravenously per mouse on day 1 after 
TBI with 9 Gy (2 × 4.5 Gy). Where indicated, DCs had been exposed to 
media alone or media and alum (240 µg/ml, exposure for 2 h).
B cell lymphoma model. To investigate GvL activity of transferred donor 
T cells, we used luciferase transgenic A20 (A20luc) B cell leukemia that had 
been previously demonstrated to migrate primarily to the BM, with second-
ary infiltration of the spleen and other lymphoid organs when injected intra-
venously at the time of BMT (Zeiser et al., 2006). Animals were injected 
with A20luc cells (BALB/c background, 5 × 105) 2 d before administration 
of the T cells from C57BL/6 donors.
Peritoneal sample collection and UA measurement. A total of 3 ml of 
PBS (Invitrogen) was injected i.p. using an 18-gauge × 1.5 needle (B/Braun) 
of GvHD patients compared with patients without GvHD 
(Fig. 5 B). Furthermore, we observed higher frequencies of 
IL-1-producing leukocytes in the peripheral blood of patients 
with GvHD (Fig. 5 C), and enhanced IL-1 expression in 
biopsies of intestine (Fig. 5 D) and skin (not depicted) from 
patients with acute GvHD. Finally, IL-17A was detected in 
intestinal biopsies from patients with grade 4 GvHD (Fig. 5 E).
In summary, our report provides the first experimental 
evidence that the conditioning therapy before allo-HCT 
generates PAMPs and DAMPs, which can activate the Nlrp3 
inflammasome during the early phase of the procedure and 
induce acute GvHD. We show that multiple intestinal cell sub-
sets express pro–IL-1 after allo-HCT, underlining its broad 
function as a key proinflammatory cytokine. Furthermore, 
our data suggest that pro–IL-1 induction in the intestines of 
conditioned mice not only depends on signals of the enteric 
microflora, but also on a positive feedback loop regulated by 
IL-1 itself. Upon irradiation- or chemotherapy-induced tis-
sue damage, enteric bacteria–derived PAMPs deliver the first 
signal needed for pro–IL-1 synthesis. The second signal, 
leading to inflammasome activation and subsequent secretion 
of bio-active IL-1, is provided by uric acid released from 
damaged cells. Consistent with a very early conditioning-
induced Nlrp3 inflammasome activation, depletion of IL-1, 
blockade of IL-1R, or depletion of UA by uricase were signifi-
cantly more efficient when started early (24 h before trans-
plantation) rather than late (on day 5). The DAMP UA was 
also increased after chemotherapy-based conditioning and 
Nlrp3 inhibition improved survival in mice. Recent studies 
suggest a possible role for Th17 cells in the pathogenesis of 
acute GVHD (Kappel et al., 2009; Yu et al., 2011), but the 
innate signaling molecules driving this response were not 
defined. In this study, we identify an Nlrp3 inflammasome 
and IL-1–dependent mechanism for allogeneic Th17 dif-
ferentiation that may contribute to the development of acute 
GVHD. Collectively, our observations emphasize the role of 
a conditioning therapy–mediated insult to the intestinal mucosa 
which leads to PAMP/DAMP-mediated Nlrp3 inflamma-
some activation and IL-1 release, with subsequent intestinal 
priming of an allogeneic Th17 response that may contribute 
to systemic severe GvHD. Moreover, our findings are of 
major importance for the future design of prophylactic strate-
gies targeting IL-1. Our data suggest that directed thera-
peutics targeting the Nlrp3 inflammasome or depletion of the 
DAMP uric acid could reduce the consequences of intestinal 
damage not only in the setting of allo-HCT but also in pa-
tients suffering from infection or undergoing chemotherapy 
and radiotherapy.
MATERIALS AND METHODS
Human subjects. We collected all samples after approval by the ethics 
committee of the Albert-Ludwigs University (Freiburg, Germany; Protocol 
number: 267/11) and after written informed consent. Intestinal tissue biop-
sies, skin biopsies, and peripheral blood samples were collected in a prospec-
tive manner from individuals undergoing allo-HCT with or without GvHD. 
GvHD grading was performed on the basis of histopathology. Staining for 
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iodide (eBioscience) were used to differentiate between viable, necrotic, and 
apoptotic cells. The following definitions were used to analyze T cell differ-
entiation: TEM, CD62Llow/CD44+; TCM, CD62L+/CD44+; TN, CD62L+/
CD44. Data were acquired with a CyanADP (Beckman Coulter) or a FAC-
SCanto II (BD), and then analyzed with FlowJo 7/8 software (Tree Star).
Immune reconstitution. To analyze the kinetics of immune reconstitu-
tion, BM-only recipient mice were sacrificed on days 40 and 70 after allo-
HCT, and the spleens were stained for the donor marker and the respective 
lineage marker.
T cell proliferation/polarization assay. For analysis of T cell prolifera-
tion in vitro, CD4+ T cells from BALB/c mice were purified by positive selec-
tion with anti-CD4 magnetic microbeads (Miltenyi Biotec), labeled with 
1 µM CFSE (Molecular Probes) as previously described (Zeiser et al., 2007) 
and exposed to LPS-exposed allogeneic BMDCs from C57BL/6 mice for 96 h. 
For cytokine production assays, CD4+ T cells were isolated by negative 
selection and with subsequent CD62L-positive selection (both from Miltenyi 
Biotec) as indicated and co-cultured with GMCSF-DCs preexposed to LPS 
(20 ng/ml) or control for 120 h.
IL-1, IL-6, IFN-, and IL-17A ELISA. A mouse IL-1 ELISA kit 
(OptEIA; BD) was used to determine the serum levels in mice according to 
the manufacturer’s instructions from 50 µl of serum. Mouse IL-17A (eBio-
science), IL-6 (BD), and IFN- (BD) ELISA kits were used to determine the 
cytokine levels in the co-culture supernatants.
Serum cytokine measurements by bead array. The levels of IFN-, TNF, 
IL-6, IL-10, IL-12p70, and MCP-1 were analyzed from serum of recipient mice 
on day 7 after allo-HSCT with the CBA Inflammation kit (BD).
Conventional and immunofluorescence microscopy. Tissues were 
embedded in OCT and cryopreserved at 80°C. 5-µm-thick fresh frozen 
sections were mounted on positively charged, precleaned microscope slides 
(Superfrost/Plus; Thermo Fisher Scientific) and stored at 80°C. For mor-
phological assessment, tissues were stained with hematoxylin/eosin accord-
ing to standard protocols. Evaluation of the stained tissue sections was 
performed on an Axioplan 2 (Carl Zeiss) microscope. Standard objectives 
used were 20×/numerical aperture 0.45 and 40×/numerical aperture 0.60. 
Microscopic photos were obtained using a Spot digital camera.
Reagents. Anakinra (Kineret; Amgen) was diluted with PBS and used at a 
concentration of 10 µg/ml in vitro. Uricase (MP Biomedical), 10 µg/100 µl 
of PBS (Invitrogen), and 5 mg of glibenclamide (InvivoGen) was dissolved in 
200 ml of DMSO and then diluted with PBS. LPS was obtained from Invivo-
Gen (Ultrapure LPS-EK from E. coli K12). The blocking anti–mouse IL-1 
monoclonal antibody was provided by H. Gram and T. Jung (Novartis).
Isolation of LP lymphocytes (LPLs). Mice were sacrificed and intes-
tines were flushed with PBSCa/Mg after dissection of fat and mesenteric 
tissue and excision of Peyer’s patches. 1-cm pieces of longitudinally opened 
and PBSCa/Mg-washed intestine were then incubated with HBSS con-
taining 2 mM EDTA, 10 mM Hepes, 5% FCS, 1% P/S, and 1 mM DTT. 
After 15 min of incubation on a shaker at 37°C, intraepithelial lymphocytes 
and epithelium were separated via 100-µm filters. EDTA incubation and 
filter separation was repeated once before intestine pieces were washed 
with PBSCa/Mg and incubated in PBS+Ca/+Mg with FCS (5%), Collagenase 
II (300 u/ml; Gibco), and DNase I (0.1 mg/ml; Roche) on a shaker at 
37°C. Cells in suspension were then purified on a 40/80% Percoll gradient 
(Biochrom). For FACS sorting, cells were stained for CD11c (APC, clone 
N418; eBioscience) and CD11b (APC-eFluor780, clone M1/70; eBioscience) 
and sorted on a BD FACSAria device. DC subsets were then plated in com-
plete RPMI in 96-well plates. For intracellular IL-1 staining, cells were 
fixed as described above and stained with anti–pro-IL1 (eBioscience; 
clone NJTEN3).
after the mouse had been sacrificed. Of this amount, 1 ml was recollected 
and immediately processed on ice for UA measurement. UA measurement 
was by QuantiChrom Uric Acid Assay kit (peak absorbance at 590 nm; Bio-
Assay Systems) according to the manufacturer’s instructions.
Drug treatment. Mice received Uricase (10 µg) in 100 µl of PBS i.p. on 
days 1, 0, 1, 4, and 8. Anakinra was given at a dose of 200 µg in 100 µl of PBS 
i.p. on day 1, 0, 1, 2, 4, 6, and 8. A monoclonal antagonistic anti–mouse IL-1 
antibody was injected at a dose of 200 µg in 200 µl of PBS i.p. 24 h before 
TBI or 5 d after TBI. The mice were injected i.p. with 500 µg/kg glybu-
ride (Nlrp3 inhibitor) or the formulation vehicle (DMSO) in 100 µl PBS on 
day 0, 1, 4, and 8. Etanercept (Enbrel, TNF inhibitor) was given at a dose of 
1 mg/kg on days 5, 8, 11, 13, 15, 18, 21, and 24. For gastrointestinal decon-
tamination, C57BL/6 mice were given 2.5 mg/ml neomycin or 1 mg/ml 
ciprofloxacin in drinking water 7 d before TBI.
Western blot. For human samples and murine splenic samples, cell pellets 
were resuspended using lysis buffer containing RIPA, protease (Santa Cruz 
Biotechnology, Inc.), and phosphatase (Sigma-Aldrich) inhibitor cocktail, 
and then incubated on ice (10 min) and centrifuged down (10,000 rpm, 4°C, 
10 min). The supernatants were collected and stored at 20°C. Protein 
concentration was determined by BCA assay (Thermo Fisher Scientific) fol-
lowing the manufacturer’s instructions.
Total cell protein was separated in 4–12% SDS-PAGE gels (Invitrogen), 
transferred on polyvinylidene fluoride (PVDF) membranes (GE Healthcare), 
and probed with specific antibodies. Immunoreactive polypeptides were detected 
by chemiluminescence using Electro-Chemi Luminescence reagents (GE 
Healthcare). For detection of cleaved caspase-1, we used an anti–cleaved cas-
pase-1 rabbit mAb (D57A2; Cell Signaling Technology) for human samples 
or an anti-cleaved caspase-1 p10 rabbit mAb (sc-514; Santa Cruz Biotechnol-
ogy, Inc.; 1:500) for murine samples. As secondary antibodies, we used HRP-
conjugated anti–rabbit antibody (Cell Signaling Technology) for detection of 
the anti-cleaved caspase-1 antibodies (1:10,000) and HRP conjugated anti–
mouse antibody for detection of the anti–-actin Ab (1:2750). For murine 
tissue analysis, terminal ileum was isolated, cleaned of fecal content, and lysed 
in NP-40 buffer. After snap-freezing in liquid nitrogen and thawing, tissue 
lysates were analyzed by Western Blot using standard SDS PAGE protocols 
with polyclonal anti–IL-1 antibody (AF401; R&D Systems) and an ECL-
based ChemoCam System (Intas).
qPCR of the intestines and skin for IL-1 and TNF. Total RNA was 
extracted from intestine and skin using QIAGEN RNA isolation kits accord-
ing to the manufacturer’s instructions. Quantitative RT-PCR was per-
formed with SYBR-green on an ABI prism 7700 sequence detection system 
(Applied Biosystems). For each gene, the results were normalized to ribo-
somal protein L27 (RPL27) and given as 2Ct values normalized to intes-
tine and skin from control animals. The results are represented as mean ± SD 
of three independent experiments. The detailed information about oligo-
nucleotide primers and conditions used are available upon request.
Flow cytometry. The following antibodies were used for flow cytometry 
analysis: anti-CD11c (Pacific blue, clone, N418; BioLegend), anti-CD3e 
(FITC, clone, 145-2C11; eBioscience), anti-CD4 (Pacific blue, clone, RM4-5; 
BioLegend; PE-Cy5, clone, GK1.5; eBioscience), anti-CD8 (FITC, clone, 
53–6.7; BD), anti–IL-1R (Alexa Fluor 647, clone, JAMA147; ABD Serotec), 
anti-CD62L (clone, MEL-14; BioLegend), anti-TCR (FITC, clone, H97-
597; eBioscience). For intracellular FoxP3-staining of splenocytes and for 
staining of co-cultured allogeneic T cells, FoxP3 staining kit (eBioscience) 
was used and cells were stained with anti-FoxP3 (clone FJK-16s; BD), IFN- 
(clone XMG1.2; eBioscience), anti-IL17A (PE-Cy7, clone eBio17B7; eBio-
science; Brilliant Violet 421, clone TC11-18H10; BioLegend), and anti-IL-1 
(fluorescein, clone, 166931). For intracellular cytokine staining of splenocytes, 
Cytofix/Cytoperm kit (BD) was used and cells were stained with anti-IL17A 
(clone TC11-18H10; BD), anti–IL-4 antibody (clone 11B11; eBioscience), 
or IFN- (clone XMG1.2, eBioscience). Annexin V (BD) and propidium 
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